Immuneering partners with leading pharmaceutical / biotech companies to provide insight into the biological impact of medicines, find new targets, and develop predictors of response. Our MIT-trained team and proprietary algorithms robustly identify key markers and mechanisms.
- Immuneering announces the publication of “Defining the Transcriptional and Cellular Landscape of Type 1 Diabetes in the NOD Mouse” in PLoS ONE
- Immuneering celebrates 5 years in business
- Immuneering CEO Ben Zeskind to speak at the 4th Translational Medicine Conference
- Jason Funt Joins Immuneering as VP, Computational Biology
- Max Artyomov Appointed Co-Chair of Immuneering’s Scientific Advisory Board
News and Publications